Roles of combined functional catechol-o-methyltransferase genotypes in Chinese Parkinson’s disease: A cross-sectional survey
Objective: To investigate the association of the most common functional catechol-O-methyltransferase (COMT) gene haplotypes with risk to develop of Parkinson's disease (PD) and the association…Safety and efficacy of pardoprunox for patients with Parkinson’s disease: A meta-analysis
Objective: The aim of this meta-analysis is to synthesize evidence from published randomized controlled trials (RCTs) about the safety and efficacy of Pardoprunox for Patients…The kinase Fyn mediates levodopa induced dyskinesias in Parkinson´s disease
Objective: To pharmacologically manipulate the kinase Fyn as a novel target to control levodopa induced dyskinesias. Background: The management of levodopa induced dyskinesias (LID) in…Motor fluctuations in relation to plasma concentrations following a single-dose of levodopa/carbidopa microtablets in advanced Parkinson’s disease
Objective: The aim of this study was to characterize the levodopa and carbidopa plasma concentration in relation to blinded motor function ratings. This is a…Changes in serum amino acid levels with progression of Parkinson’s disease
Objective: The purpose of this study was to analyze changes in serum amino acid profile with progression of Parkinson's disease (PD). Background: PD is a…Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson’s disease center
Objective: To describe the frequency, characteristics and potential risk factors for Dopamine Agonist Withdrawal Syndrome (DAWS). Background: Dopamine agonists are a mainstay of treatment for…Conversion to IPX066, extended-release carbidopa-levodopa, in advanced Parkinson’s disease patients: Dosing patterns
Objective: Describe the dosing patterns in advanced Parkinson's disease (PD) patients who completed conversion to IPX066 from other levodopa formulations. Background: IPX066 is an extended-release…Critical path for Parkinson’s II: Global regulatory agencies support the use of dopamine transporter neuroimaging as an enrichment biomarker to enable clinical trials in early Parkinson’s disease
Objective: This presentation focuses on neuroimaging of the Dopamine Transporter as an enrichment biomarker in clinical trials of Parkinson's disease (PD). Background: The Critical Path…Conversion of patients from immediate release carbidopa-levodopa (IR CD-LD) and sustained release carbidopa-levodopa (SR CD-LD) to extended-release carbidopa-levodopa (ER CD-LD) in clinical practice
Objective: To evaluate the real-world response of patients who are converted from IR CD-LD and SR CD-LD to ER CD-LD in an academic practice. Background:…Lessons-experienced in the creation of a global public-private consortium with the goal of advancing treatments that hold most potential for delayed disease progression in Parkinson’s disease – Critical path for Parkinson’s (CPP)
Objective: The path is summarized that led to the creation of a global public-private-partnership uniting an international non-profit charity, Parkinson's UK, a global non-profit organization,…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.